E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Virus Diseases [C02] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the immunogenicity of two 0.25 mL IM doses of Fluad or Fluzone influenza vaccines in terms of post-vaccination geometric mean titers (GMTs), seroprotection rates and seroconversion rates, as measured by HI assay in subjects aged between 6 to <36 months, 36 to <60 months and 6 to <60 months.
To evaluate the safety and tolerability of one and two 0.5 mL IM doses of Fluad or
Fluzone influenza vaccines in unprimed healthy children aged between 6 to <36 months, 36 to <60 months and 6 to <60 months. |
|
E.2.2 | Secondary objectives of the trial |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Children of 6 to <60 months of age, whose parents/legal guardians have given written informed consent prior to study entry.
2. In good health as determined by:
a. medical history,
b. physical examination,
c. clinical judgment of the investigator.
3. Able to comply with all study procedures and available for all clinic visits and telephone calls scheduled in the study.
4.Informed consent was obtained for all the subjects before enrollment into the study after the nature of the study had been explained. |
|
E.4 | Principal exclusion criteria |
1. Any serious disease, such as:
a. cancer,
b. autoimmune disease (including rheumatoid arthritis),
c. diabetes mellitus,
d. chronic pulmonary disease,
e. acute or progressive hepatic disease,
f. acute or progressive renal disease,
g. acute or progressive neurological or neuromuscular disease;
2. History of any anaphylaxis or serious reaction following administration of vaccine, or hypersensitivity to eggs, egg protein, chicken feathers, influenza viral protein, or any other vaccine component, chemically related substance, or component of the potential packaging materials;
3. Known or suspected impairment/alteration of immune function, including:
a. immunosuppressive therapy such as systemic corticosteroids known to be associated with the suppression of hypothalamic-pituitary-adrenal (HPA) axis or chronic use of inhaled high-potency corticosteroids within 60 days prior to Visit 1,
b. cancer chemotherapy,
c. receipt of immunostimulants within 60 days prior to Visit 1,
d. receipt of parenteral immunoglobulin preparation, blood products, and/or plasma derivatives within 3 months prior to Visit 1 or planned during the full length of the study,
e. known HIV infection or HIV-related disease;
4. History of Guillain-Barré syndrome;
5. Bleeding diathesis;
6. Surgery planned during the study period;
7. Receipt of another investigational agent within 90 days, or before completion of the safety follow-up period in another study, whichever is longer, prior to enrollment and unwilling to refuse participation in another clinical study through the end of the study;
8. Receipt of another vaccine within 2 weeks (for inactivated vaccines) or 4 weeks (for live vaccines) prior to Visit 1;
9. Laboratory-confirmed influenza disease within 6 months prior to Visit 1;
10. Ever received two doses of an influenza vaccine before the study, either in two consecutive influenza seasons or in one single influenza season;
11. Receipt of an influenza vaccine within 6 months prior to Visit 1;
12. Experienced a temperature ≥38.0°C (≥100.4°F ) and/or any acute illness within 3 days prior to Visit 1;
13. Any condition, which in the opinion of the Investigator would preclude the subject, on a medical basis, from enrollment or that might interfere with the evaluation of the study objectives. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
• Number and percentage of children with at least one local or systemic reaction between 1 and 7 days after any vaccine injection.
• Number and percentage of children with at least one AE between ay 1 and ay 50.
• Number and percentage of subjects with at least one SAE or one AE necessitating
a physician’s visit or consultation and/or leading to study discontinuation between
Day 1 and study termination (day 211).
• GMTs at Day 1, and Day 29;
• Day 29/Day 1 and Day 50/Day 1 geometric mean titer ratios (GMRs);
• percentage of children achieving seroconversion1 at Day 29;
• percentage of children achieving seroprotection2 at Day 1, and at Day 29. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
• Number and percentage of children with at least one local or systemic reaction between 1 and 7 days after any vaccine injection.
• Number and percentage of children with at least one AE between ay 1 and ay 50.
• Number and percentage of subjects with at least one SAE or one AE necessitating
a physician’s visit or consultation and/or leading to study discontinuation between
Day 1 and study termination (day 211).
• GMTs at Day 1, and Day 29;
• Day 29/Day 1 and Day 50/Day 1 geometric mean titer ratios (GMRs);
• percentage of children achieving seroconversion1 at Day 29;
• percentage of children achieving seroprotection2 at Day 1, and at Day 29. |
|
E.5.2 | Secondary end point(s) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
|
E.8.2.4 | Number of treatment arms in the trial | 6 |
E.8.3 |
Will this trial be conducted at a single site globally?
| Yes |
E.8.4 | Will this trial be conducted at multiple sites globally? | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.2 | Trial being conducted completely outside of the EEA | Yes |
E.8.6.3 | Specify the countries outside of the EEA in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.2 | In all countries concerned by the trial years | 0 |
E.8.9.2 | In all countries concerned by the trial months | 9 |